Cancer biotech Silenseed files for a $35 million IPO
Silenseed, a biotech developing a targeted delivery system to treat cancer using the body's own defenses, filed on Friday with the SEC to raise up to $35 million in an initial public offering. The Jerusalem, Israel-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RNAI. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.